Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension (OHT)
Sponsor: Royal Perth Hospital
This PHASE4 trial investigates Hypertension and Obesity and is currently ongoing. Royal Perth Hospital leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
7 versions recorded-
Oct 2024 — Present [monthly]
Unknown PHASE4
Status: Recruiting → Unknown
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Oct 2022 — Jul 2024 [monthly]
Recruiting PHASE4
-
Oct 2021 — Oct 2022 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE4
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE4
First recorded
Jun 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Royal Perth Hospital
- The University of Western Australia
For direct contact, visit the study record on ClinicalTrials.gov .